Skip to content
AnthologyRX

Is CJC-1295/ipamorelin safe?

CJC-1295/ipamorelin is a compounded blend, not an FDA-approved finished drug. Short studies of individual ingredients cannot establish the risks of repeated use of a different combination.

Which formulation was studied?

The listing here identifies the CJC component as no-DAC, combined with ipamorelin in an injection. The published CJC-1295 trials used a long-acting, albumin-binding form and followed healthy adults for 28 or 49 days. The ipamorelin trial used IV treatment after bowel surgery. Neither was a long-term safety study of this subcutaneous combination.

Read: Teichman et al. Long-acting CJC-1295 in healthy adults; Beck et al. IV ipamorelin after bowel surgery.

Does no-DAC automatically mean safer?

No. A separate human study of long-acting CJC-1295 found that growth hormone pulses persisted even while average and trough levels rose. Long exposure and pulsatile release can coexist. The no-DAC label alone does not establish a safer hormone pattern, better recovery or a lower risk for this blend.

Read: Ionescu and Frohman. GH pulsatility after long-acting CJC-1295.

What concerns has FDA identified?

FDA describes potential immune reactions and difficulty characterizing these peptides. Its CJC-1295 discussion includes increased heart rate and systemic vasodilatory reactions, with limited clinical data.

For ipamorelin acetate, FDA cites serious events, including deaths, reported during IV use after surgery and inadequate safety information for certain other injectable routes. That report does not establish causation or a risk rate for the subcutaneous blend. A different route also does not establish safety.

Read: FDA: Bulk substances with potential significant safety risks; Beck et al. IV ipamorelin after bowel surgery.

A useful safety conversation

Share your full medical history and medication list. Confirm the exact ingredients, intended outcome, appropriate baseline assessment and when progress will be reviewed. Ask which symptoms should prompt stopping and contacting the prescriber, and what would lead to changing the plan. Testing can inform care without proving that an inadequately studied blend is safe.

Sources

  1. Teichman et al. Long-acting CJC-1295 in healthy adults

    JCEM, 2006. Short studies of GH and IGF-1 responses; not a trial of the CJC-1295/ipamorelin blend.

  2. Ionescu and Frohman. GH pulsatility after long-acting CJC-1295

    JCEM, 2006. Healthy men receiving the albumin-binding form; not the no-DAC/ipamorelin combination.

  3. Beck et al. IV ipamorelin after bowel surgery

    International Journal of Colorectal Disease, 2014. Different route, population and outcome from wellness use.

  4. FDA: Bulk substances with potential significant safety risks

    Substance-specific concerns and gaps in available safety information.

  5. FDA: Compounding questions and answers

    The distinction between compounded medications and FDA-approved drug products.

AnthologyRX
Find your treatment
Browse all treatments